The infusion of healthy stem cells into a patient—termed “stem-cell therapy”—has shown great promise for the treatment of genetic and non-genetic diseases, including mucopolysaccharidosis type 1, Parkinson's disease, multiple sclerosis, numerous immunodeficiency disorders, and aplastic anemia. Stem cells for cell therapy can be collected from the patient (autologous) or collected from another “healthy” individual (allogeneic). The use of allogenic stem cells is accompanied with the potentially fatal risk that the transplanted donor T cells will reject the patient's cells—a process termed “graft-versus-host disease.” Therefore, the use of autologous stem cells is preferred, at least from the immunological perspective. However, an obvious drawback is that inherently as “self,” they contain the disease mutation. As such, autologous cells for use in cell therapies often require genetic “correction” (i.e., gene addition or editing) prior to cell infusion and therefore the requirement for some form of nucleic acid delivery, which sets the stage for the AAV controversy discussed herein. Despite being the most clinically applied gene delivery context to date, unlike other more concerning integrating and non-integrating vectors such as retroviruses and adenovirus, those based on adeno-associated virus (AAV) have not been employed in the clinic. Furthermore, published data regarding AAV vector transduction of stem cells are inconsistent in regards to vector transduction efficiency, while the pendulum swings far in the other direction with demonstrations of AAV vector–induced toxicity in undifferentiated cells. The variation present in the literature examining the transduction efficiency of AAV vectors in stem cells may be due to numerous factors, including inconsistencies in stem-cell collection, cell culture, vector preparation, and/or transduction conditions. This review summarizes the controversy surrounding AAV vector transduction of stem cells, hopefully setting the stage for future elucidation and eventual therapeutic applications.
Get full access to this article
View all access options for this article.
References
1.
AsokanA, ConwayJC, PhillipsJL, et al.Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol, 2010; 28:79–82.
2.
HirschML, FaganBM, DumitruR, et al.Viral single-strand DNA induces p53-dependent apoptosis in human embryonic stem cells. PLoS One, 2011; 6:e27520.
3.
BotquinV, Cid-ArreguiA, SchlehoferJR. Adeno-associated virus type 2 interferes with early development of mouse embryos. J Gen Virol, 1994; 75:2655–2662.
4.
Friedman-EinatM, GrossmanZ, MileguirF, et al.Detection of adeno-associated virus type 2 sequences in the human genital tract. J Clin Microbiol, 1997; 35:71–78.
5.
SamulskiRJ, MuzyczkaN. AAV-mediated gene therapy for research and therapeutic purposes. Ann Rev Virol, 2014; 1:427–451.
6.
XieQ, BuW, BhatiaS, et al.The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A, 2002; 99:10405–10410.
7.
GriegerJC, SamulskiRJ. Packaging caapacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol, 2005; 79:9933–9944.
8.
GonçalvesMA. Adeno-associated virus: from defective virus to effective vector. Virol J, 2005; 2:43.
9.
GaoG, VandenbergheL, WilsonJ. New recombinant serotypes of AAV vectors. Curr Gene Ther, 2005; 5:285–297.
SamulskiRJ, BernsKI, TanM, et al.Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A, 1982; 79:2077–2081.
12.
SamulskiRJ, ChangLS, ShenkT. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol, 1989; 63:3822–3828.
13.
HirataRK, RussellDW. Design and packaging of adeno-associated virus gene targeting vectors. J Virol, 2000; 74:4612–4620.
14.
WangZ, MaHI, LiJ, et al.Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther, 2003; 10:2105–2111.
15.
McCartyDM, MonahanPE, SamulskiRJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther, 2001; 8:1248–1254.
AsuriP, BartelMA, VazinT, et al.Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther, 2012; 20:329–338.
21.
KhanIF, HirataRK, WangP-R, et al.Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol Ther, 2010; 18:1192–1199.
22.
MitsuiK, SuzukiK, AizawaE, et al.Gene targeting in human pluripotent stem cells with adeno-associated virus vectors. Biochem Biophys Res Commun, 2009; 388:711–717.
23.
XiaoX, LiJ, SamulskiRJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol, 1996; 70:8098–8108.
24.
VollweilerJL, ZielskeSP, ReeseJS, et al.Hematopoietic stem cell gene therapy: progress toward therapeutic targets. Bone Marrow Transplant, 2003; 32:1–7.
25.
EllisBL, HirschML, BarkerJC, et al.A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J, 2013; 10:74.
26.
VeldwijkMR, SellnerL, StiefelhagenM, et al.Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34+ peripheral blood progenitor cells. Cytotherapy, 2010; 12:107–112.
27.
PonnazhaganS, MukherjeeP, WangXS, et al.Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. J Virology, 1997; 71:8262–8267.
28.
QingK, MahC, HansenJ, et al.Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med, 1999; 5:71–77.
29.
BartlettJS, KleinschmidtJ, BoucherRC, et al.Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'γ)2 antibody. Nat Biotechnol, 1999; 17:181–186.
30.
HandaA, MuramatsuS, QiuJ, et al.Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J Gen Virol, 2000; 81:2077–2084.
31.
LiM, JayandharanGR, LiB, et al.High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum Gene Ther, 2010; 21:1527–1543.
32.
McMahonJM, ConroyS, LyonsM, et al.Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors. Stem Cell Dev, 2006; 15:87–96.
33.
ItoH, GoaterJJ, TiyapatanaputiP, et al.Light-activated gene transduction of recombinant adeno-associated virus in human mesenchymal stem cells. Gene Ther, 2004; 11:34–41.
34.
JuX, LouS, WangW, et al.Effect of hydroxyurea and etoposide on transduction of human bone marrow mesenchymal stem and progenitor cell by adeno-associated virus vectors. Acta Pharmacol Sin, 2004; 25:196–202.
35.
RaptiK, StillitanoF, KarakikesI, et al.Effectiveness of gene delivery systems for pluripotent and differentiated cells. Mol Ther Methods Clin Dev, 2015; 2:14067.
36.
WalshCE, NienhuisAW, SamulskiRJ, et al.Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest, 1994; 94:1440–1448.
37.
MillerJL, DonahueRE, SellersSE, et al.Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad Sci U S A, 1994; 91:10183–10187.
38.
ZhouSZ, CooperS, KangLY, et al.Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med, 1994; 179:1867–1875.
39.
GoodmanS, XiaoX, DonahueRE, et al.Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood, 1994; 84:1492–1500.
40.
LingC, BhukhaiK, YinZ, et al.High-efficiency transduction of primary human hematopoietic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci Rep, 2016; 6:35495.
41.
KaussMA, SmithLJ, ZhongL, et al.Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2. Hum Gene Ther, 2010; 21:1129–1136.
42.
VeldwijkMR, SellnerL, StiefelhagenM, et al.Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34(+) peripheral blood progenitor cells. Cytotherapy, 2010; 12:107–112.
43.
SongL, KaussMA, KopinE, et al.Optimizing the transduction efficiency of human hematopoietic stem cells using capsid-modified AAV6 vectors in vitro and in a xenograft mouse model in vivo. Cytotherapy, 2013; 15:986–998.
44.
BelayE, DastidarS, VandenDriesscheT, et al.Transposon-mediated gene transfer into adult and induced pluripotent stem cells. Curr Gene Ther, 2011; 11:406–413.
45.
KurpadC, MukherjeeP, WangXS, et al.Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted expression from parvovirus B19p6 promoter in primary human hematopoietic progenitor cells. J Hematother Stem Cell Res, 1999; 8:585–592.
46.
PonnazhaganS, WeigelKA, RaikwarSP, et al.Recombinant human parvovirus B19 vectors: erythroid cell-specific delivery and expression of transduced genes. J Virol, 1998; 72:5224–5230.
47.
WangXS, YoderMC, ZhouSZ, et al.Parvovirus B19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic progenitor cells. Proc Natl Acad Sci U S A, 1995; 92:12416–12420.
48.
BroxmeyerHE, CooperS, Etienne-JulanM, et al.Cord blood transplantation and the potential for gene therapy. Gene transduction using a recombinant adeno-associated viral vector. Ann N Y Acad Sci, 1995; 770:105–115.
49.
ChatterjeeS, LiW, WongCA, et al.Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood, 1999; 93:1882–1894.
50.
SantatL, PazH, WongC, et al.Recombinant AAV2 transduction of primitive human hematopoietic stem cells capable of serial engraftment in immune-deficient mice. Proc Natl Acad Sci U S A, 2005; 102:11053–11058.
51.
HandaA, MuramatsuS, QiuJ, et al.Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J Gen Virol, 2000; 81:2077–2084.
52.
SmithLJ, Ul-HasanT, CarvainesSK, et al.Gene transfer properties and structural modeling of human stem cell-derived AAV. Mol Ther, 2014; 22:1625–1634.
53.
WangJ, ExlineCM, DeClercqJJ, et al.Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol, 2015; 33:1256–1263.
54.
YangQ, MamounasM, YuG, et al.Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum Gene Ther, 1998; 9:1929–1937.
55.
SellnerL, StiefelhagenM, KleinschmidtJA, et al.Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp Hematol, 2008; 36:957–964.
56.
SongL, LiX, JayandharanGR, et al.High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo. PloS One, 2013; 8:e58757.
57.
SchuhmannNK, PozzoliO, SallachJ, et al.Gene transfer into human cord blood-derived CD34(+) cells by adeno-associated viral vectors. Exp Hematol, 2010; 38:707–717.
58.
DeverDP, BakRO, ReinischA, et al.CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature, 2016; 539:384–389.
59.
SatherBD, IbarraGSR, SommerK, et al.Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Science Transl Med, 2015; 7:307.
60.
AlexanderIE, RussellDW, MillerAD. Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results. Hum Gene Ther, 1997; 8:1911–1920.
61.
NathwaniAC, HanawaH, VandergriffJ, et al.Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. Gene Ther, 2000; 7:183–195.
62.
MalikP, McQuistonSA, YuXJ, et al.Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line. J Virol, 1997; 71:1776–1783.
63.
JiangY, JahagirdarBN, ReinhardtRL, et al.Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 2002; 418:41–49.
64.
UccelliA, MorettaL, PistoiaV. Mesenchymal stem cells in health and disease. Nat Rev Immunol, 2008; 8:726–736.
65.
ShengW, FengZ, SongQ, et al.Modulation of mesenchymal stem cells with miR-375 to improve their therapeutic outcome during scar formation. Am J Transl Res, 2016; 8:2079–2087.
66.
PagnottoMR, WangZ, KarpieJC, et al.Adeno-associated viral gene transfer of transforming growth factor-β1 to human mesenchymal stem cells improves cartilage repair. Gene Ther, 2007; 14:804–813.
67.
KimJH, ParkS-N, SuhH. Generation of insulin-producing human mesenchymal stem cells using recombinant adeno-associated virus. Yonsei Med J, 2007; 48:109–119.
68.
GabrielN, SamuelR, JayandharanGR. Targeted delivery of AAV-transduced mesenchymal stromal cells to hepatic tissue for ex vivo gene therapy. J Tissue Eng Regen Med, 2015Jun5. DOI: 10.1002/term.2034 [Epub ahead of print].
69.
BaoC, GuoJ, LinG, et al.TNFR gene-modified mesenchymal stem cells attenuate inflammation and cardiac dysfunction following MI. Scand Cardiovasc J, 2008; 42:56–62.
70.
KumarS, MahendraG, NagyTR, et al.Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy. Hum Gene Ther, 2004; 15:1197–1206.
71.
WangQ, ZhangZ, DingT, et al.Mesenchymal stem cells overexpressing PEDF decrease the angiogenesis of gliomas. Biosci Rep, 2013; 33:e00019.
72.
ChngK, LarsenSR, ZhouS, et al.Specific adeno-associated virus serotypes facilitate efficient gene transfer into human and non-human primate mesenchymal stromal cells. J Gene Med, 2007; 9:22–32.
73.
KangY, LiaoW, YuanZ, et al.In vitro and in vivo induction of bone formation based on adeno-associated virus-mediated BMP-7 gene therapy using human adipose-derived mesenchymal stem cells. Acta Pharmacol Sin, 2007; 28:839–849.
74.
WeiG, AnG, ShiZ, et al.Suppression of microRNA-383 enhances therapeutic potential of human bone-marrow-derived mesenchymal stem cells in treating spinal cord injury via GDNF. Cell Physiol Biochem, 2017; 41:1435–1444.
75.
ShevchenkoEK, MakarevichPI, TsokolaevaZI, et al.Transplantation of modified human adipose derived stromal cells expressing VEGF165 results in more efficient angiogenic response in ischemic skeletal muscle. J Transl Med, 2013; 11:138.
76.
ChamberlainJR, SchwarzeU, WangPR, et al.Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science, 2004; 303:1198–1201.
77.
ChamberlainJR, DeyleDR, SchwarzeU, et al.Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. Mol Ther, 2008; 16:187–193.
78.
KimbrelEA, LanzaR. Pluripotent stem cells: the last 10 years. Regen Med, 2016; 11:831–847.
79.
HendriksWT, WarrenCR, CowanCA. Genome editing in human pluripotent stem cells: approaches, pitfalls, and solutions. Cell Stem Cell, 2016; 18:53–65.
80.
BraamSR, DenningC, van den BrinkS, et al.Improved genetic manipulation of human embryonic stem cells. Nat Methods, 2008; 5:389–392.
81.
CaoF, XieX, GollanT, et al.Comparison of gene-transfer efficiency in human embryonic stem cells. Mol Imaging Biol, 2010; 12:15–24.
82.
MooreJC, AtzeK, YeungPL, et al.Efficient, high-throughput transfection of human embryonic stem cells. Stem Cell Res Ther, 2010; 1:23.
83.
HohensteinKA, PyleAD, ChernJY, et al.Nucleofection mediates high-efficiency stable gene knockdown and transgene expression in human embryonic stem cells. Stem Cells, 2008; 26:1436–1443.
84.
DingW, ZhangL, YanZ, et al.Intracellular trafficking of adeno-associated viral vectors. Gene Ther, 2005; 12:873–880.
85.
XiaoP, SamulskiRJ. Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol, 2012; 86:10462–10473.
86.
ZhongL, LiW, YangZ, et al.Impaired nuclear transport and uncoating limit recombinant adeno-associated virus 2 vector-mediated transduction of primary murine hematopoietic cells. Hum Gene Ther, 2004; 15:1207–1218.
87.
DouarA, PoulardK, StockholmD, et al.Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol, 2001; 75:1824–1833.
88.
Vihinen-RantaM, SuikkanenS, ParrishCR. Pathways of cell infection by parvoviruses and adeno-associated viruses. J Virol, 2004; 78:6709–6714.
89.
SummerfordC, SamulskiRJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 1998; 72:1438–1445.
90.
O'DonnellJ, TaylorKA, ChapmanMS. Adeno-associated virus-2 and its primary cellular receptor—cryo-EM structure of a heparin complex. Virology, 2009; 385:434–443.
91.
BartlettJS, WilcherR, SamulskiRJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol, 2000; 74:2777–2785.
92.
MurlidharanG, SamulskiRJ, AsokanA. Biology of adeno-associated viral vectors in the central nervous system. Front Mol Neurosci, 2014; 7:76.
93.
KaminskyPM, KeiserNW, YanZ, et al.Directing integrin-linked endocytosis of recombinant AAV enhances productive FAK-dependent transduction. Mol Ther, 2012; 20:972–983.
94.
NonnenmacherM, WeberT. Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe, 2011; 10:563–576.
95.
SanliogluS, BensonPK, YangJet al.Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by Rac1 and phosphatidylinositol-3 kinase activation. J Virol, 2000; 74:9184–9196.
96.
GirodA, WobusCE, ZádoriZ, et al.The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol, 2002; 83:973–978.
97.
StahnkeS, LuxK, UhrigS, et al.Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology, 2011; 409:77–83.
98.
GriegerJC, SnowdyS, SamulskiRJ. Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J Virol, 2006; 80:5199–5210.
99.
DuanD, YueY, YanZ, et al.Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest, 2000; 105:1573–1587.
100.
JohnsonJS, LiC, DiPrimioN, et al.Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol, 2010; 84:8888–8902.
101.
MonahanPE, LothropCD, SunJ, et al.Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther, 2010; 18:1907–1916.
102.
ZhangFL, JiaSQ, ZhengSP, et al.Celastrol enhances AAV1-mediated gene expression in mice adipose tissues. Gene Ther, 2011; 18:128–134.
103.
Popa-WagnerR, PorwalM, KannM, et al.Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J Virol, 2012; 86:9163–9174.
104.
GriegerJC, JohnsonJS, Gurda-WhitakerB, et al.Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions. J Virol, 2007; 81:7833–7843.
105.
NicolsonSC, SamulskiRJ. Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J Virol, 2014; 88:4132–4144.
106.
PelekanosRA, TingMJ, SardesaiVS, et al.Intracellular trafficking and endocytosis of CXCR4 in fetal mesenchymal stem/stromal cells. BMC Cell Biol, 2014; 15:15.
107.
ZhangY, FoudiA, GeayJF, et al.Intracellular localization and constitutive endocytosis of CXCR4 in human CD34+ hematopoietic progenitor cells. Stem Cells, 2004; 22:1015–1029.
108.
FurthauerM, Gonzalez-GaitanM. Endocytosis, asymmetric cell division, stem cells and cancer: unus pro omnibus, omnes pro uno. Mol Oncol, 2009; 3:339–353.
109.
JohnsonJS, SamulskiRJ. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol, 2009; 83:2632–2644.
110.
ThomasCE, StormTA, HuangZ, et al.Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol, 2004; 78:3110–3122.
111.
SipoI, FechnerH, PinkertS, et al.Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction. Gene Therapy, 2007; 14:1319–1329.
112.
FerrariFK, SamulskiT, ShenkT, et al.Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol, 1996; 70:3227–3234.
113.
KelichJM, MaJ, DongB, et al.Super-resolution imaging of nuclear import of adeno-associated virus in live cells. Mol Ther, 2015; 2:15047.
114.
SeisenbergerG, RiedMU, EndreT, et al.Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science, 2001; 294:1929–1932.
115.
LisowskiL, LauA, WangZ, et al.Ribosomal DNA integrating rAAV-rDNA vectors allow for stable transgene expression. Mol Ther, 2012; 20:1912–1923.
116.
WangZ, LisowskiL, FinegoldMJ, et al.AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence. Mol Ther, 2012; 20:1902–1911.
117.
ZhouX, ZengX, FanZ, et al.Adeno-associated virus of a single-polarity DNA genome is capable of transduction in vivo. Mol Ther, 2008; 16:494–499.
118.
Fisher-AdamsG, WongKKJr, PodsakoffG, et al.Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood, 1996; 88:492–504.
119.
NakaiH, StormTA, KayMA. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol, 2000; 74:9451–9463.
120.
HauswirthWW, BernsKI. Origin and termination of adeno-associated virus DNA replication. Virology, 1977; 78:488–499.
121.
BevingtonJM, NeedhamPG, VerrillKC, et al.Adeno-associated virus interactions with B23/nucleophosmin: identification of sub-nucleolar virion regions. Virology, 2007; 357:102–113.
122.
SchuhmannNK, PozzoliO, SallachJ, et al.Gene transfer into human cord blood–derived CD34+ cells by adeno-associated viral vectors. Exp Hematol, 2010; 38:707–717.
123.
KleinRL, MeyerEM, PeelAL, et al.Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol, 1998; 150:183–194.
124.
GraySJ, FotiSB, SchwartzJW, et al.Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther, 2011; 22:1143–1153.
125.
PaternaJC, MoccettiT, MuraA, et al.Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther, 2000; 7:1304–1311.
126.
TolmachovOE, SubkhankulovaT, TolmachovaT. Silencing of transgene expression: a gene therapy perspective. In: MolinaFM, ed. Gene Therapy—Tools and Potential Applications. www.intechopen.com/books/gene-therapy-tools-and-potential-applications/silencing-of-transgene-expression-a-gene-therapy-perspective (last accessed March3, 2017).
127.
PröschS, SteinJ, StaakK, et al.Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler, 1996; 377:195–201.
128.
KongQ, WuM, HuanY, et al.Transgene expression is associated with copy number and cytomegalovirus promoter methylation in transgenic pigs. PLoS One, 2009; 4:e6679.
129.
GerolamiR, UchR, JordierF, et al.Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther, 2000; 7:1286–1292.
LiM, LiuG-H, BelmonteJC. Navigating the epigenetic landscape of pluripotent stem cells. Nat Rev Mol Cell Biol, 2012; 13:524–535.
132.
TakahashiK, TanabeK, OhnukiM, et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007; 131:861–872.
133.
ChenD, MurphyB, SungR, et al.Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function. Gene Ther, 2003; 10:991–998.
134.
FlotteTR, AfioneSA, SolowR, et al.Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem, 1993; 268:3781–3790.
135.
ZukerM. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res, 2003; 31:3406–3415.
136.
FarréD, RosetR, HuertaM, et al.Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res, 2003; 31:3651–3653.
137.
MesseguerX, EscuderoR, FarréD, et al.PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics, 2002; 18:333–334.
138.
MegíasJ, YáñezA, MorianoS, et al.Direct Toll-like receptor-mediated stimulation of hematopoietic stem and progenitor cells occurs in vivo and promotes differentiation toward macrophages. Stem Cells, 2012; 30:1486–1495.
139.
DelaRosaO, DalemansW, LombardoE. Toll-like receptors as modulators of mesenchymal stem cells. Front Immunol, 2012; 3:182.
KawasakiT, KawaiT. Toll-like receptor signaling pathways. Front Immunol, 2014; 5:461.
142.
TakedaK, KaishoT, AkiraS. Toll-like receptors. Annu Rev Immunol, 2003; 21:335–376.
143.
LaredjLN, BeardP. Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells. J Virol, 2011; 85:13133–13143.
144.
ZhuJ, HuangX, YangY. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest, 2009; 119:2388–2398.
145.
NishiyaT, DeFrancoAL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem, 2004; 279:19008–19017.
146.
GarnerE, MartinonF, TschoppJ, et al.Cells with defective p53-p21-pRb pathway are susceptible to apoptosis induced by p84N5 via caspase-6. Cancer Res, 2007; 67:7631–7637.
147.
MomcilovicO, KnoblochL, FornsaglioJ, et al.DNA damage responses in human induced pluripotent stem cells and embryonic stem cells. PLoS One, 2010; 5:e13410.
148.
DravidG, YeZ, HammondH, et al.Defining the role of Wnt/β-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. Stem Cells, 2005; 23:1489–1501.
149.
GrandelaC, PeraMF, WolvetangEJ. p53 is required for etoposide-induced apoptosis of human embryonic stem cells. Stem Cell Res, 2008; 1:116–128.
150.
LiuJC, GuanX, RyanJA, et al.High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis. Cell Stem Cell, 2013; 13:483–491.
151.
ZhangM, YangC, LiuH, et al.Induced pluripotent stem cells are sensitive to DNA damage. Genomics Proteomics Bioinformatics, 2013; 11:320–326.
152.
DumitruR, GamaV, FaganBM, et al.Human embryonic stem cells have constitutively active Bax at the Golgi and are primed to undergo rapid apoptosis. Mol Cell, 2012; 46:573–583.
153.
ChengS, Schmidt-GrimmingerDC, MurantT, et al.Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Devel, 1995; 9:2335–2349.
154.
LongworthMS, LaiminsLA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev, 2004; 68:362–372.
155.
TsubouchiT, FisherAG. Reprogramming and the pluripotent stem cell cycle. Curr Topics Devel Biol, 2013; 104:223–241.
156.
RuizS, PanopoulosAD, HerreríasA, et al.A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity. Curr Biol, 2011; 21:45–52.
157.
HongY, StambrookPJ. Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc Natl Acad Sci U S A, 2004; 101: 14443–14448.
158.
AladjemMI, SpikeBT, RodewaldLW, et al.ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol, 1998; 8:145–155.
159.
StambrookPJ, TichyED. Preservation of genomic integrity in mouse embryonic stem cells. Adv Exp Med Biol, 2010; 695:59–75.
160.
FragkosM, BeardP. Mitotic catastrophe occurs in the absence of apoptosis in p53-null cells with a defective G1 checkpoint. PLoS One, 2011; 6:e22946.
161.
ChaurushiyaMS, WeitzmanMD. Viral manipulation of DNA repair and cell cycle checkpoints. DNA Repair (Amst), 2009; 8:1166–1176.
162.
CollacoRF, BevingtonJM, Kalman-MalteseVBV, et al.Adeno-associated virus and adenovirus coinfection induces a cellular DNA damage and repair response via redundant phosphatidylinositol 3-like kinase pathways. Virology, 2009; 392:24–33.
163.
VogelR, SeyffertM, StrasserR, et al.Adeno-associated virus type 2 modulates the host DNA damage response induced by herpes simplex virus 1 during coinfection. J Virol, 2012; 86:143–155.
164.
SmithS, WellerSK. HSV-I and the cellular DNA damage response. Future Virol, 2015; 10:383–397.
165.
FuX, WangH, ZhangX. High-frequency intermolecular homologous recombination during herpes simplex virus-mediated plasmid DNA replication. J Virol, 2002; 76:5866–5874.
166.
GillespieKA, MehtaKP, LaiminsLA, et al.Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. J Virol, 2012; 86:9520–9526.
167.
McKinneyCC, HussmannKL, McBrideAA. The role of the DNA damage response throughout the papillomavirus life cycle. Viruses, 2015; 7:2450–2469.
168.
LouS, LuoY, ChengF, et al.Human parvovirus B19 DNA replication induces a DNA damage response that is dispensable for cell cycle arrest at phase G2/M. J Virol, 2012; 86:10748–10758.
169.
LuoY, QiuJ. Human parvovirus B19: a mechanistic overview of infection and DNA replication. Future Virol, 2015; 10:155–167.
170.
TobiaschE, RabreauM, GeletnekyK, et al.Detection of adeno-associated virus DNA in human genital tissue and in material from spontaneous abortion. J Med Virol, 1994; 44:215–222.
171.
KiehlK, SchlehoferJR, SchultzR, et al.Adeno-associated virus DNA in human gestational trophoblastic disease. Placenta, 2002; 23:410–415.
172.
TenenbaumL, LehtonenE, MonahanPE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther, 2003; 3:545–565.
173.
MingozziF, HighKA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet, 2011; 12:341–355.
174.
HewittFC, LiC, GraySJ, et al.Reducing the risk of adeno-associated virus (AAV) vector mobilization with AAV type 5 vectors. J Virol, 2009; 83:3919–3929.
175.
ReyaT, MorrisonSJ, ClarkeMF, et al.Stem cells, cancer, and cancer stem cells. Nature, 2001; 414:105–111.
176.
RajK, OgstonP, BeardP. Virus-mediated killing of cells that lack p53 activity. Nature, 2001; 412:914–917.
